On 9 November 2026, Shanghai Henlius announced that Brazil’s National Health Surveillance Agency (Anvisa) has approved Poherdy®, biosimilar to Genentech’s Perjeta® (pertuzumab). Poherdy® is the first biosimilar pertuzumab approved in Brazil.
Poherdy® (HLX11) was developed by Shanghai Henlius, which licensed the exclusive commercialisation rights to Organon under a 2022 agreement for all regions outside China, Macau, Hong Kong and Taiwan.
Poherdy® was the first pertuzumab biosimilar approved in the US (November 2025) and EU (April 2026). In the US, a BPCIA patent challenge by Genentech/Roche against Henlius/Organon regarding Poherdy® was settled in January 2026 on confidential terms, with no details of any planned US launch of Poherdy® being disclosed to date. In China, HLX11 was approved in May 2026 as Hanbeiyou®.
In September 2026, Biocon announced that, in partnership with Brazilian state-owned pharmaceutical laboratory, Bahiafarma, and Brazilian biotechnology company, Bionovis, it has entered a 10-year contract to supply Bmab 1500 (pertuzumab) in Brazil. Biocon signed a global settlement and licence agreement with Genentech for Bmab 1500 (Pebrilzo®) in October 2026, permitting Biocon to launch Pebrilzo® in the EU/UK in Q1/2027, in the US in Q3/2028 and in 2026-2028 in other Rest of World countries (or earlier in certain circumstances).
Approvals for pertuzumab biosimilars have been granted in India for Intas’ product (December 2024), Zydus’ Sigrima™ (June 2024, subject to ongoing litigation) and Enzene’s Pertuza®/Perzea® (launched September 2025). In Russia, Biocad’s Pertuvia™ (May 2025, subject to litigation) and R-Pharm’s Persinthia™ (February 2026) are approved.
In June 2026, EirGenix announced that it signed an agreement with an undisclosed company for the licensing and commercialisation of its pertuzumab biosimilar, EG1206A, in Japan. This followed a 2025 global commercialisation deal with Sandoz for EG1206A, excluding Japan and a number of other countries in Asia.
